Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) CEO Purchases $86,200.00 in Stock

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) CEO Seth Lederman purchased 4,000 shares of the company’s stock in a transaction that occurred on Thursday, May 15th. The shares were bought at an average cost of $21.55 per share, with a total value of $86,200.00. Following the transaction, the chief executive officer now directly owns 4,005 shares of the company’s stock, valued at $86,307.75. The trade was a 80,000.00% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.

Tonix Pharmaceuticals Price Performance

Tonix Pharmaceuticals stock opened at $28.00 on Friday. Tonix Pharmaceuticals Holding Corp. has a 52-week low of $6.76 and a 52-week high of $659.20. The firm has a fifty day moving average of $18.93 and a 200-day moving average of $20.92. The firm has a market capitalization of $205.10 million, a P/E ratio of -0.01 and a beta of 1.63. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its quarterly earnings data on Monday, May 12th. The company reported ($2.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.23) by $0.39. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The company had revenue of $2.43 million during the quarter, compared to analyst estimates of $2.55 million. As a group, analysts predict that Tonix Pharmaceuticals Holding Corp. will post -1762.5 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently commented on TNXP shares. StockNews.com started coverage on shares of Tonix Pharmaceuticals in a research report on Monday, February 10th. They set a “sell” rating for the company. Noble Financial reaffirmed an “outperform” rating and set a $70.00 price target on shares of Tonix Pharmaceuticals in a research report on Thursday, March 20th.

Institutional Investors Weigh In On Tonix Pharmaceuticals

Several large investors have recently made changes to their positions in TNXP. PFG Investments LLC acquired a new stake in shares of Tonix Pharmaceuticals in the fourth quarter worth $72,000. Commonwealth Equity Services LLC acquired a new stake in shares of Tonix Pharmaceuticals in the fourth quarter worth $40,000. Geode Capital Management LLC boosted its stake in shares of Tonix Pharmaceuticals by 1,600.1% in the fourth quarter. Geode Capital Management LLC now owns 1,971,894 shares of the company’s stock valued at $650,000 after purchasing an additional 1,855,907 shares during the period. Northern Trust Corp purchased a new position in shares of Tonix Pharmaceuticals in the fourth quarter valued at $162,000. Finally, Jane Street Group LLC boosted its stake in shares of Tonix Pharmaceuticals by 5,932.3% in the fourth quarter. Jane Street Group LLC now owns 1,662,682 shares of the company’s stock valued at $548,000 after purchasing an additional 1,635,119 shares during the period. Institutional investors and hedge funds own 82.26% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.